Abstract: Methods for treating, preventing and predicting a subject's risk of developing breast cancer are provided.

Abstract: Methods for treating, preventing and predicting a subject's risk of developing breast cancer are provided.

Abstract: Methods for treating, preventing and predicting a subject's risk of developing breast cancer are provided. In one aspect, a method of predicting a subject's risk of developing breast cancer is provided, wherein the method includes: (a) determining the frequency in a breast tissue sample of CD44+, CD24? breast epithelial cells, and (b) predicting that the subject has a relatively elevated risk of developing breast cancer if the frequency of CD44+, CD24? breast epithelial cells is decreased compared to a first control frequency of CD44+, CD24? breast epithelial cells; or (c) predicting that the subject has a relatively reduced risk of developing breast cancer if the frequency of CD44+ breast epithelial cells is increased compared to a second control frequency of CD44+, CD24? breast epithelial cells.

Abstract: The invention relates to the use of an antibody or a fragment thereof, specific against substance P, for the manufacture of a medicament for therapeutic treatment of a cancer expressing NK1 receptor and/or a ErbB receptor family member (i.e. the epidermal growth factor receptors family), by direct administration to a mammal, including a human. The administration of an antibody against substance P to a panel of breast cancer cell lines, inhibits HER2 activation and expression, causing a downregulation of different genes involved in cell cycle progression, like cyclin D1, cyclin E, cdk4 and cdk2. A decrease in proliferation and an arrest in G1 phase of cell cycle are observed. On the other hand, the antibody causes an induction of apoptosis.